Details of the Drug

General Information of Drug (ID: DM1I8LU)

Drug Name
Coenzyme A
Synonyms
coenzyme A; CoASH; CoA-SH; Zeel; 85-61-0; Depot-Zeel; CoA; HSCoA; Coenzym A; Coenzyme ASH; co-enzyme-A; UNII-SAA04E81UX; HS-CoA; SAA04E81UX; CHEBI:15346; 3'-phosphoadenosine-(5')diphospho(4')pantatheine; Coenzyme A hydrate; co-A; Co-A-SH; Reduced CoA; 3'-phosphoadenosine 5'-{3-[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl] dihydrogen diphosphate}
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 767.5
Topological Polar Surface Area (xlogp) -5.8
Rotatable Bond Count (rotbonds) 18
Hydrogen Bond Donor Count (hbonddonor) 10
Hydrogen Bond Acceptor Count (hbondacc) 21
Chemical Identifiers
Formula
C21H36N7O16P3S
IUPAC Name
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
Canonical SMILES
CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O
InChI
InChI=1S/C21H36N7O16P3S/c1-21(2,16(31)19(32)24-4-3-12(29)23-5-6-48)8-41-47(38,39)44-46(36,37)40-7-11-15(43-45(33,34)35)14(30)20(42-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-31,48H,3-8H2,1-2H3,(H,23,29)(H,24,32)(H,36,37)(H,38,39)(H2,22,25,26)(H2,33,34,35)/t11-,14-,15-,16+,20-/m1/s1
InChIKey
RGJOEKWQDUBAIZ-IBOSZNHHSA-N
Cross-matching ID
PubChem CID
87642
ChEBI ID
CHEBI:15346
CAS Number
85-61-0
DrugBank ID
DB01992
TTD ID
D0W3NA
VARIDT ID
DR00302

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Pantothenate kinase (Bact coaA) TTSEOPJ COAA_ECOLI Inhibitor [2]
Carnitine acyltransferase (CRAT) TTC8M31 CACP_HUMAN Inhibitor [2]
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [2]
Phosphopantetheine adenylyltransferase (PPAT) TT4YO0Z COASY_HUMAN Inhibitor [2]
Staphylococcus DHNA-CoA synthase (Stap-coc menB) TT8HWCD MENB_STAAC Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Graves disease carrier protein (SLC25A16) DTNU9EW GDC_HUMAN Substrate [3]
Mitochondrial coenzyme A transporter SLC25A42 (SLC25A42) DTU4HKJ S2542_HUMAN Substrate [4]
Peroxisomal membrane protein PMP34 (SLC25A17) DTYR5U7 PM34_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.01E-05 0.65 1.53
Peroxisomal membrane protein PMP34 (SLC25A17) DTP PMP34 7.38E-02 -8.98E-02 -7.93E-01
Mitochondrial coenzyme A transporter SLC25A42 (SLC25A42) DTP SLC25A42 3.36E-02 -1.22E-01 -8.00E-01
Graves disease carrier protein (SLC25A16) DTP GDC 5.07E-03 2.87E-01 1.23E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3044).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Biochemical characterization of a new mitochondrial transporter of dephosphocoenzyme A in Drosophila melanogaster. Biochim Biophys Acta Bioenerg. 2017 Feb;1858(2):137-146.
4 A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3',5'-diphosphate in human mitochondria. J Biol Chem. 2009 Jul 3;284(27):18152-9.
5 The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7.
6 Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes. 2011 February; 60(2): 644-651.
7 EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. Brain Res. 2006 Nov 6;1118(1):168-75.
8 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
9 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
10 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
11 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
12 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
13 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
14 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 NME DIGEST. Drug News & Perspect 2002, 15(8):519, ISSN 0214-0934.
17 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.